Moolec Science SA Ordinary Shares (MLEC)vsRoyalty Pharma Plc (RPRX)
MLEC
Moolec Science SA Ordinary Shares
$8.10
+18.59%
HEALTHCARE · Cap: $5.27M
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 31057% more annual revenue ($2.44B vs $7.83M). RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
MLEC
Hold44
out of 100
Grade: D
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MLEC.
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 948.0% year-over-year
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Trading at 11.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MLEC
The strongest argument for MLEC centers on Revenue Growth. Revenue growth of 948.0% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : MLEC
The primary concerns for MLEC are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 7.21 is elevated, increasing financial risk.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
MLEC profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
MLEC is growing revenue faster at 948.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 44/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moolec Science SA Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company is headquartered in Luxembourg.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?